Effect of Itraconazole on the Pharmacokinetics of Apatinib
he primary purpose of this study is to investigate potential pharmacokinetic interaction in healthy volunteers when apatinib is administered in combination with itraconazole. Secondary objective is evaluating the safety and tolerability of apatinib alone and when co-administered with itraconazole.
Neoplasms
DRUG: Apatinib Mesylate Tablets|DRUG: Itraconazole Capsules
Area under the plasma concentration versus time curve (AUC) of Apatinib, 0~72h after apatinib administration
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, From first administration to the seventh day after last administration|Peak Plasma Concentration (Cmax) of Apatinib, 0~72h after apatinib administration
he primary purpose of this study is to investigate potential pharmacokinetic interaction in healthy volunteers when apatinib is administered in combination with itraconazole. Secondary objective is evaluating the safety and tolerability of apatinib alone and when co-administered with itraconazole.